The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.

Mol Cancer · 2025 · PMC12051277 · PMID 40320521

Europe PMC DOI

hedged sentence

0.1599

closest p · 3.2× alpha

0.1599

boldest claim

The sentences

showed a trendp = 0.1599not close (p > 0.1)

At the endpoint measurement, Pioglitazone-treated mice also showed a trend of reduced tumor weight ( p = 0.1599) (Suppl.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.